UPC CFI 1830/2026

May 26, 2026·EP4397760 Unitary patent · COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF

Case details: Status
Written Phase
Action
Infringement
Category
Main infringement action
Parties: Claimants
ToolGen, Inc.NPE
Representatives
Mark Didmon-Potter Clarkson
Respondents
Vertex Pharmaceuticals IncorporatedOperating co.
Lonza Netherlands B.V.Operating co.
Representatives
Rutger Kleemans-Freshfields
Nerissa Teeuwen-Freshfields
Division: The Hague LD
Judges: Edger Brinkman
Margot Kokke
Vincenzo Carni
Michael Alt
Technology: Chemistry
Biotechnology
Language: English
First decided: Sep 15, 2026
EPO Opposition: Vossius & Partner Patentanwälte Rechtsanwälte mbB2026-01-21
Vertex Pharmaceuticals Incorporated2026-01-21

How this compares

The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.

	Infringement found	Median days to first decision
All UPC	53% (62/117)	124
The Hague LD	Locked	Locked
Judge Edger Brinkman	Locked	Locked
Judge Margot Kokke	Locked	Locked
Judge Vincenzo Carni	—	Locked
Judge Michael Alt	Locked	Locked

At the UPC: ToolGen, Inc. (1 case)·Vertex Pharmaceuticals Incorporated (1 case)

Start 14-day free trialAlready a user? Sign in

Related cases

All proceedings on this patent

Start a free trial to see how each one ended.

More cases: The Hague LD·2026

Decisions

2026-09-15
InfringementPublic
Summary: The Hague Local Division order (judge-rapporteur Kokke, 15 Sep 2026) in ToolGen, Inc. v Vertex Pharmaceuticals Incorporated and Lonza Netherlands B.V. (EP 4 397 760, CRISPR/Cas9 composition; product Casgevy): the defendants' R. 190 RoP application for production of documents disclosed in UK proceedings is dismissed because it would circumvent the UK use restrictions; their R. 361 RoP application to dismiss the claims for injunctive and corrective relief as manifestly bound to fail is dismissed; the statement-of-defence deadline is confirmed as 25 Sep 2026 and the parties are invited to comment on Art. 33(3) UPCA.
Show the legal issues (3)
- R. 190 RoP production of documents subject to a UK CPR 31.22 collateral-use undertaking
- R. 361 RoP reserved for clear-cut cases
- Art. 33(3) UPCA handling of an announced counterclaim for revocation

Documents

Show all 192 documents

Document title	Date	Public
Communication	2026-10-09	Not public
Receipt	2026-10-07	Not public
Cover sheet	2026-10-07	Not public
Document	2026-10-07	Not public
Communication	2026-10-07	Not public
Receipt	2026-10-07	Not public
Cover sheet	2026-10-07	Not public
Document	2026-10-07	Not public
Communication	2026-10-07	Not public
Receipt	2026-10-07	Not public